

Index to Volume Thirty

Index of Issues: January, 1-98; February, 99-186; March, 187-272; April, 273-368; May, 369-476; June, 477-532; July, 533-592; August, 593-670; September, 671-735; October, 737-802; November, 803-870; December, 871-934.

INDEX OF AUTHORS

A
Abel M, 362
Abraham CD, 549
Abrahamowicz M, 581
ACSGA Investigators, 6
Adams AL, 764
Adams EJ, 379
Adler B, 874
Ahlman K, 114
Ahmed HJ, 114
Alarcon J, 273
Alary M, 46
Alcalá B, 395
Alexander L, 193
Almirall R, 788
Alter MJ, 340
Amestoy GM, 593
Amida X, 664
Anderson JE, 719
Anderson K, 91
Anderson LA, 30
Anoma CK, 284
Antolín I, 395
Antonio MAD, 568
Apter D, 120
Aral SO, 39, 71, 221, 419, 750
Armenian HK, 199
Aronson N, 713
Arreaza L, 395
Ashley-Morrow R, 310
Awasana AA, 483
Ayoub M, 731

B
Bachmann LH, 20, 335
Bäckman A, 205
Baker MA, 650
Bali M, 523
Bandala C, 284
Barcellos NT, 166
Barivelo T, 664
Bass DC, 71
Becker TM, 764
Begley E, 211
Behets F, 262, 664
Beltramini JF, 526
Berman SM, 49, 472, 528
Bernstein DI, 774
Bernstein KT, 199
Biro FM, 752
Blair R, 866
Blandford JM, 502
Blazes DL, 713
Blejan C, 866
Boehner CW, 774
Boelle P-Y, 6
Boerma JT, 779
Bolan G, 49
Borrell N, 395
Bosch FX, 788
Boselli F, 707
Boskey ER, 107
Bowen AM, 571
Branovskaja M, 680
Brennan CH, 340
Brewer T, 914
Brodine S, 545, 713

C
Brown C, 575
Brown DR, 246
Brown P, 689
Brunham RC, 297
Buchanan K, 273
Bull SS, 15
Burkhardt G, 664
Burk RD, 575
Burman WJ, 399
Butler N, 609

D
Cachero J, 395
Callahan DB, 340, 645
Calvet H, 49
Campbell P, 33
Campos PE, 273
Carrel D, 174
Carreño F, 280
Carrillo C, 273
Carvalho SE, 694
Casey S, 874
Casper C, 713
Castellanos S, 195
Castle PE, 575
Catala I, 788
Celetano DD, 185
Chagas C, 694
Chaoanachan T, 320
Chaw JK, 509, 661
Chemeris G, 680
Chen R, 600
Chen S, 362, 609
Chernesky M, 345, 880, 905
Cherpes TL, 405
Chesson HW, 419
Chilongozi D, 516
Chirossi G, 707
Choi K-H, 91
Chong S, 345
Chrisnadarmani VAMA, 671
Christensen NO, 262
Chu B-C, 614
Ciaffli L, 671
Ciesielski CA, 650
Cintorino M, 680
Claeys P, 137
Clark R, 839
Cocuccio B, 157
Cohen DA, 844
Cohen MS, 516
Cohn DL, 399
Conde-Glez CJ, 266, 549
Cone RA, 107
Connell FA, 99
Connolly C, 1, 241
Coplan PM, 246
Corey L, 174, 425, 713
Cosgrove Sweeney YT, 568
Costa MC, 581
Costa PL, 694
Courtous B, 273
Craig T, 83
Cranston B, 575
Crosby RA, 57, 211, 634, 909
Crum NF, 713
Cruz-Valdez A, 549

E
Eckert LO, 357
Edmunds WJ, 379
Egger M, 129
Ellen JM, 234, 533, 825
Engelberg R, 174
Ennis DM, 512
Erokhina O, 680
Escoffery C, 575
Espinosa E, 292
Esquivel CA, 195
Essex M, 187
Essien EJ, 110
Esteban JI, 470
Esteban R, 470
Ethier K, 809
Ettiègne-Traore V, 284
Ezcaraga MLB, 195

F
Fairchok MP, 901
Fairley CK, 886
Falk L, 205
Farley TA, 75, 654, 839, 844
Fawzi WW, 187
Feijó G, 694
Feldblum PJ, 440
Fenton J, 33
Fernández-Esquer ME, 110
Fernandez I, 809
Fichtenberg CM, 825
Fife KH, 246
Flaks RC, 399
Font R, 788

G
Gala P, 335
Gallinelli A, 707
García MJ, 280
Garcia PJ, 379
Garin CA, 756
Garland S, 362, 886
Garnett GP, 149, 379
Gaydos CA, 64, 306, 539, 769
Gaydos JC, 539, 769
Geisler WM, 160
Ghys PD, 284
Gift TL, 502
Gilbert BC, 719
Gilbert LK, 193
Gillespie B, 216
Gilroy C, 129
Ginocchio RHS, 99
Girasek DC, 531
Girolomoni G, 157
Gisselquist D, 183
Gittelsohn J, 149
Glezerman M, 835
Gmach RD, 440
Golden MR, 490, 742
Goldie SJ, 369
Gollub EL, 433
Gómez CA, 91
Gooding E, 483
Goossens H, 25
Goossens W, 25
Gotuzzo E, 273
Gourley PJ, 399
Greenland S, 411
Gregorich SE, 91
Gregson S, 779
Grenfell BT, 388
Grewal N III, 530
Grice A, 362
Grinstead O, 91
Grosshans JF, 193
Grujberg A, 680
Grujnberga V, 680
Guan J, 803
Guardia J, 470
Gubinelli E, 157
Guerino C, 114
Gunnarsson E, 114
Gunn RA, 340, 645
Gutierrez AA, 195
Gutierrez L, 273
Guzmán D, 10

H

Haikala O, 737
Hale S, 901
Hammer GP, 919
Hanchard B, 575
Handsfield HH, 49, 490, 742
Hardick J, 64
Hatzell T, 440
Hawes SE, 357
Hayes P, 886
Hebb JK, 756
Heckman TG, 134
Hees PS, 107
Hernández-Castellanos A, 266
Hernández-Márquez C, 549
Hernandez MT, 661
Herrera L, 593
Herrero R, 593, 788
Hillier SL, 71, 257, 273, 405, 568
Hirose T, 629
Hobbs MM, 516
Hoffman IF, 516
Hogben M, 490, 742
Holmes KK, 273, 379, 490, 742
Homan RK, 440
Hook EW III, 20, 335, 369, 512, 850
Hoover DR, 433
Horner P, 129
Hotta H, 629
Howard M, 880
Howell MR, 539, 769
Howe SR, 774
Hoxworth T, 83
Hsieh Y-H, 64, 769
Hughes J, 273, 756
Hu L, 803
Hultunen-Back E, 737
Humblet O, 818
Hussain A, 588
Hutapea N, 178
Hutchinson ML, 575

I

Ieven M, 25
Irwin K, 30, 866
Ivanchenko O, 680
Iwasawa A, 629

J

Jacobson LP, 199
Jacobs RJ, 859
Jamison D, 327
Jang D, 345, 880
Jansen KU, 246
Jayaraman GC, 315
Jeansson S, 588
Jeeyapant S, 320
Jenkins FJ, 199
Jennings JM, 234
Johansson B, 680
Johnson G, 654, 844
Johnson S, 83
Johnson SM, 533
Jolley L, 193
Jones M, 335, 850
Jónsdóttir K, 249
Jordan N, 723
Juárez-Figueroa L, 266
Judson FN, 562
Junquera ML, 292
Jurstrand M, 205

K

Juschenko A, 680
Kahn RH, 654, 700, 844
Kaldor J, 362
Kapiga SH, 187
Karim SSA, 149
Karwalajtys T, 880
Kaun K, 362
Kautainen H, 737
Kaydos-Daniels SC, 516
Kazembe PN, 516
Keel KB, 571
Kellogg TA, 331, 919
Kenny GE, 756
Kent CK, 49, 331, 368, 813
Kerani RP, 742
Kilmari PH, 320
Kiltikari R, 120
Kim AA, 813
Kip E, 516
Kissinger P, 49, 75, 214, 731, 839
Kiweu IE, 187
Klausner JD, 331, 368, 509, 609, 661, 813, 874, 919
Kleter B, 137
Kljukina L, 680
Kobayashi I, 629
Koenig L, 809
Kohl K, 650
Koroku M, 629
Koumans EH, 700
Kozachenko V, 680
Krantz E, 174, 310
Kraut-Becher JR, 221
Kristjánsson M, 249
Krohn MA, 405
Krunfly C, 593
Kruse N, 664
Kumamoto Y, 629
Kumari S, 523
Kumwenda N, 185
Kunishima Y, 629
Kus J, 64

L

Lackey PC, 512
Laga M, 284
Lagergård T, 114
Lammens C, 25
Land DJ, 348
Lang D, 57
Lantero MI, 10
Lapidus JA, 764
Latka M, 433
Lau A, 896
Lau JTF, 600, 620, 827
Lazcano-Ponce E, 549
Lazzarotto T, 157
Lee JH, 872
Lee JK, 234
Lee M, 803
Lehman JS, 764
Le Pont F, 6
Leutscher PDC, 262
Levine D, 634
Levine WC, 472
Liang G, 803
Li H, 443
Li L, 803
Limones DEC, 195
Lindberg M, 205

M

Lind I, 178
Lipova E, 680
Lister NA, 886
Liu H, 327
Li X, 327
Llanes R, 10, 443
Llop A, 10, 443
Lloveras B, 788
Lobo TT, 694
Loeb L, 874
Lolis S, 844
Londner MS, 143
Loria D, 593
Louie B, 331, 919
Loveless MO, 764
Lowndes CM, 46
Lumpkins J, 335
Lurie MN, 149
Lyons EE, 30

N

Macaluso M, 20
MacKellar D, 425
MacKinnon S, 880
Ma E, 327
Magid DJ, 30
Magnus M, 75, 731, 839
Maher JE, 75, 83
Mahony J, 345
Majkowski JM, 854
Manongi R, 187
Margolis HS, 340
Marina RB, 226
Markowitz LE, 49, 320, 650, 700
Marrazzo JM, 99, 890
Martell M, 470
Martín DH, 49, 844
Martínez I, 10
Martin I, 896
Martinko T, 901
Martinson F, 516
Masenga EJ, 187
Mastro TD, 320
Matos E, 593
Maupin RT, 728
Maurice CE, 284
Mayaud P, 483
Mayberry R, 723
Mbivzo E, 588
Mbwanja J, 114
McClure M, 129
McFarland W, 331, 609, 919
McFarlane M, 15
McGee ZA, 530
McKee KT Jr, 539, 769
McLean CA, 650
Medland NA, 886
Medrano JC, 195
Meheus A, 25
Mehta SD, 143
Meijer CJLM, 593, 788
Merchant J, 689
Mertz GJ, 801
Mestad RE, 728
Mettey A, 909
Meyerhoff AS, 859
Meyers M, 134
Meyerson BE, 614
Meyn LA, 257, 405
Mhalu F, 114
Michaud JM, 533
Migliani R, 262

O

O'Brien ME, 731
Oh MK, 49, 689
Oksanen H, 120
Ólafsson JH, 249
Olcén P, 205
O'Leary M, 362
Olmsted SS, 257
Osterhaus ADME, 639
Otero L, 280, 292, 395
Otto B, 671
Ovaskainen OT, 388
Owens ML, 124

P

Paavonen J, 120, 737
Padian NS, 556
Paffel JM, 872
Page-Shafer K, 331, 919
Pajanidi J, 680
Palacio V, 280
Palefsky JM, 575
Palma S, 10

Parker KA, 39
 Partohuoya S, 671
 Patel D, 216
 Patnaik JL, 15, 562
 Patten J, 671
 Patton DL, 568
 Paukku M, 120
 Paul C, 818
 Paz-Bailey G, 320
 Pech N, 6
 Perdue T, 425
 Peterman TA, 75, 83, 731
 Petrovichev N, 680
 Pettifor A, 455
 Pfister JR, 797
 Pigott D, 335
 Platt L, 46
 Pliati R, 866
 Podistov J, 680
 Potterat JJ, 89, 490
 Poumerol G, 362
 Pourbohloul B, 297
 Preiksaitsis J, 33
 Price MA, 516
 Primary Care STI Study Group (GITSAP), 876
 Prince MA, 593
 Proyecto Concordia Collaborative Group, 593
 Pshepurko A, 680
 Puolakkainen M, 120

Q
 Quer J, 470
 Quinn TC, 539, 769
 Quint W, 137

R
 Rabe LK, 568
 Ramarokoto C-E, 262
 Ramirez-Arcos S, 443
 Ramos BPL, 195
 Ransom RL, 49
 Raphael TL, 614
 Ratelle S, 866
 Rattray C, 575
 Ravaoalimalala EV, 262
 Raveh D, 835
 Ray K, 523
 Read RR, 315
 Regional Infertility Prevention Program, 472
 Rein MF, 348
 Rekan ML, 297
 Renjifo B, 187
 Reppucci ND, 348
 Reunala T, 737
 Rhodes SD, 449
 Rice P, 71
 Richardson-Alston G, 75, 731
 Richardson E, 880
 Richter HE, 71
 Rietmeijer CA, 15, 399, 562, 659
 Rinaldi J, 874
 Roberts CM, 797
 Roberts JN, 226
 Rogers C, 433
 Rohan LC, 257
 Rohan TE, 581
 Rojas C, 246
 Romanowski B, 33, 226
 Rompalo A, 143, 533

Rosana Y, 25
 Rose E, 57, 211, 634
 Rosenthal SL, 752, 774, 801, 854
 Ross MW, 110
 Rothenberg R, 478
 Rotheram MJ, 803
 Rothman RE, 143
 Rousseau M-C, 581
 Rousset D, 262
 Ruben M, 443
 Rudy E, 411, 685
 Rust G, 723
 Ruutu P, 737
 Ryan CA, 39

S
 Sadan O, 835
 Safarova E, 39
 Sahin-Hodoglugil NN, 455
 Saka T, 629
 Salas EV, 195
 Salcedo C, 395
 Sam NE, 187, 588
 Samra Z, 794, 835
 Samson ET, 671
 Sánchez C, 280, 292
 Sánchez J, 273
 Sánchez-Zamorano L, 549
 Sanders WM, 512
 Sansom S, 685
 Santelli J, 719
 Santopietro R, 680
 Satcher D, 723
 Sauca G, 395
 Sauder DN, 124
 Schachter J, 575, 905
 Schaffrin JK, 700
 Scherf E, 794
 Schiffman M, 575
 Schillinger JA, 49
 Schim van der Loeff M, 483
 Schwarz S, 609
 Seattle Young Men's Survey Team, 425
 Secura GM, 425
 Sellors J, 345, 880
 Shabalova I, 680
 Shafer M-A, 545
 Shakarishvili A, 39
 Shao JF, 187
 Shibusaki SC, 556
 Shimizu T, 629
 Short MB, 752, 854
 Siddiqi O, 262
 Silverthorn M, 134
 Simões-Barbosa A, 694
 Simpson T, 689
 Sinclair MF, 650
 Singh A, 315, 497
 Sitati S, 137
 Sizemore JM, 512
 Skinner RB, 124
 Smith A, 886
 Snijders PJF, 788
 Soper DE, 71
 Sosa J, 10, 443
 Sozaeva L, 680
 Spear SJ, 797
 Spencer NE, 83
 St. Lawrence JS, 39, 490
 Stamm C, 71

Stamm WE, 160, 357
 Stanberry LR, 752, 801, 854
 Steingrímsson Ó, 249
 Stein ZA, 433
 Stephan K, 713
 Sternberg M, 49, 320
 Steyaert S, 137
 Stiffman M, 30
 Stine K, 890
 Stray-Pedersen B, 588
 Strickler HD, 575
 Strine T, 685
 Sturm AW, 1, 149, 241
 Sturm PDJ, 241
 Succop PA, 752
 Suchland RJ, 160, 357
 Sudigdoadi S, 25
 Sugai K, 575
 Su L, 246
 Sullivan EA, 362
 Supawitkul S, 320
 Sutama IN, 671
 Sutton TL, 901
 Su X, 178
 Svensson LA, 114
 Sweat MD, 149
 Sweet RL, 71
 Syrjänen K, 680
 Syrjänen S, 680

T
 Tabrizi S, 362, 886
 Taha TE, 185
 Takahashi S, 629
 Takeyama K, 629
 Taleo H, 362
 Tambis JA, 661
 Tanda H, 629
 Tang Y, 866
 Tao G, 866
 Tapsall JW, 178
 Tasker SA, 713
 Tawes J, 64
 Taylor-Robinson D, 129
 Temmerman M, 137
 Terndrup T, 335
 Thiede H, 425
 Thomas AG, 713
 Thomas B, 129
 Tikhonova L, 39
 Timpson S, 571
 Tosi P, 680
 Totten PA, 756
 Trepka MJ, 914
 Tsidaeva I, 680
 Tsui H, 600, 620
 Tsukamoto T, 629
 Tulloch S, 64
 Turkheimer E, 348
 Turner KR, 331

U
 Urassa M, 779
 Uribe-Salas F, 266

V
 Valdés EA, 10
 Valleroy L, 425
 Valtrex HS230017 Study Group, 226
 van den Brule AJC, 593
 van der Meijden WI, 639

van der Snoek EM, 639
 van Doornum GJJ, 639
 Van Dyck E, 284
 Van Griensven F, 320
 Van Looveren M, 25
 Vanmali T, 241
 Van Marck E, 137
 Van Renterghem L, 137
 Vansteelandt S, 137
 Vaovola G, 664
 Varela JA, 280, 292
 Vázquez F, 280, 292, 395
 Vázquez JA, 395
 Veenstra DL, 99
 Villa LL, 581
 Villar H, 395
 Vlahov D, 199
 Vuylsteke BL, 284

W
 Wald A, 174, 310, 713, 890
 Wallace MR, 713
 Walsh J, 455
 Walter E, 809
 Waltje A, 134
 Wang Q, 600
 Wang SA, 528
 Ward K, 609
 Watts D, 273
 Wegner S, 713
 Weinberg M, 645
 Weisbord JS, 914
 Weiss HL, 850
 West B, 483
 Whelan M, 866
 Whitten KL, 348
 Whittington WHL, 49, 160, 742
 Wiktor SZ, 284
 Wilkinson D, 1, 241
 Williams BG, 149
 Williams I, 919
 Williams ML, 110, 571
 Wilson TE, 809
 Wingood GM, 57, 211, 634
 Wong E, 331, 919
 Wong T, 497
 Wong W, 661
 Woodcox V, 880
 Woods R, 455
 Workowski KA, 528
 Wu Z, 803

X
 Xavier J, 694

Y
 Yacoub W, 497
 Yarber W, 134
 Yeh JM, 369
 Yin Y, 327, 803
 Yokoe D, 866
 Yuan W, 600

Z
 Zakharenko S, 680
 Zakharova T, 680
 Zenilman JM, 143
 Zhang G, 914
 Zimba D, 516
 Zuma K, 149

INDEX OF SUBJECTS

A

Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection
 Adjudicated African American adolescents, risk behavior of, 634
 Adolescents
 acceptability of urine screening for gonorrhea and chlamydia in, 850
 adjudicated African American, risk behavior of, 634
 dual use of condoms and hormonal contraceptives by, 719
 female
 nonexclusivity in romantic relationships of, 752
 topical microbicide use by, 854
 genital herpes in, HSV type 1 as predominant cause of, 797
 high-risk, discordant sexual partnerships of, 234
 HSV-2 infection in, sexual and demographic risk factors for, in Mexico, 549
 pregnant African American
 continued risky sex among, 57, 211, 214 (editorial)
 with older partners, STD prevalence among, 211, 214 (editorial)
 risk behaviors of, in Thailand, 320
 screening recommendations for, 367 (letter)
 Africa. *See also* specific countries
 bacterial vaginosis
 rapid diagnostic kit for, 483
 treatment algorithms for sex workers in, 284
 cost-effectiveness of diagnosis and treatment protocols for chlamydia and gonorrhea in, 455
 genital ulcer disease in, etiology and HIV co-infection in, 114
 HIV-1 transmission in, migration and, 149
 HIV prevalence in, 183, 185 (letters)
 HIV risk factors in, 183, 185 (letters), 262
 HPV distribution in family planning clinic attendees in, 137
 HSV type 2 infection in
 prevalence of, 187, 588
 risk factors for, 187, 262
 participatory mapping of sex trade in, 664
 sex workers in, STD treatment algorithms for, 284
 syndromic management in, role of community pharmacists in, 609
 uneven HIV prevalence in, 779
 African Americans. *See also* Race/ethnicity
 adjudicated adolescent, risk behavior of, 634
 gay, hepatitis B vaccination in, 449, 685
 pregnant adolescent
 continued risky sex among, 57
 with older partners, STD prevalence among, 211, 214 (editorial)
 Age
 cervical infection with multiple HPV types and, 581
 female, condom use and, 216
 partner
 in discordant adolescent sex partnerships, 234
 STD prevalence in adolescent girls and, 211, 214 (editorial), 234
 AIDS. *See* Human immunodeficiency virus infection
 Anal nodular herpes simplex virus infection, in AIDS, 157
 Anal warts, imiquimod 5% cream for, 124
 Anogenital warts
 5% imiquimod cream for, 124
 frequently asked questions about, 193
 Antibiotics
 prophylactic, for syphilis, 844
 topical, acceptability of to adolescent girls, 854
 Antimicrobial resistance, of *N. gonorrhoeae*
 in Canada, 896
 in Cuba, 11, 443
 in India, 523
 in Indonesia, 25, 178
 in Spain, 395
 Antiretroviral therapy
 adherence to, transmission risk behaviors and, 399
 availability of, impact of on risk behaviors, 562, 765
 Argentina, HPV infection in, prevalence of in females, 593

Army recruits

 female, chlamydia prevalence in, 539, 545 (editorial)
 male, HIV-infected, human herpesvirus-8 infection in, 713
 ASTDA awards, 477, 478
 Australia, gonorrhea and chlamydia screening in, at male-only saunas, 886
 Azithromycin
 for chlamydial infection, partner-delivered partner treatment with, 49
 for incubating syphilis, cost-effectiveness of, 502
 N. gonorrhoeae resistance to, in Cuba, 443

B

Bacterial vaginosis
 glycosidase and proteinase activity in, 257
 HSV-2 infection and, 405
 in pregnancy, management of, 645
 rapid diagnostic kit for, in Gambia, 483
 syndromic management of, with/without HIV-1 coinfection, 1
 treatment algorithms for, for sex workers, in Côte d'Ivoire, 284
 Barrier contraceptives. *See also* Condom use
 acceptability and product choice as indicators of use of, 556
 Bathhouses, male-only, gonorrhea and chlamydia screening in, 886
 Belarus, sexual habits and HPV infection in females in, 680
 Birth control pills, condom use with
 by adolescents, 719
 by HIV-infected vs. non-HIV-infected women, 809
 Brazil, HIV risk factors and prevalence in, 166
 Bridge members, of adolescent sexual networks, 234

C

Canada
 gonorrhea outbreak in, 497
 N. gonorrhoeae drug resistance in, 896
 syphilis outbreak in, patient characteristics with male-to-male vs. heterosexual acquisition in, 310
 Candidal vaginitis, treatment algorithms for, for sex workers, in Côte d'Ivoire, 284
 Capture-recapture methodology, in sex trade mapping and sex worker enumeration, in Madagascar, 664
 Caribbean, drug-resistant *N. gonorrhoeae* in, 10, 443
 CDC case definition, of pelvic inflammatory disease, predictive value of clinical diagnostic codes for, 866
 Centers for Disease Control and Prevention (CDC), treatment guidelines of for chlamydia, adherence to in managed care organizations, 30
 need for revision of, 528 (letter)
 Cervical gonococcal infections, in Indonesian sex workers, 671
 Cervical neoplasia grade, STD coinfections and, in Jamaica, 575
 Cervicovaginal secretion collection, self-sampling methods for, 107, 306, 769, 880
 China. *See also* Hong Kong
 market vendors in, STD prevalence and characteristics in, 803
 STD/HIV prevention in, needs assessment for, 600
 syndromic management of male STDs in, 327
 Chlamydial heat-shock protein 60 kDa antibodies, 157
 in chronic nongonococcal urethritis, 129
 Chlamydial infection
 adolescent risk behaviors and, in Thailand, 320
 CDC guidelines for, adherence to in managed care organizations, 30
 cervical neoplasia grade and, in Jamaica, 575
 cervicovaginal specimen collection for, self-sampling methods for, 107, 306, 769, 880
 contact tracing for, genotyping and, 205
 cost-effectiveness of diagnosis and treatment protocols for, in Africa, 455
 gonococcal coinfection and, in young women, 472
 HPV infection and, in men who have sex with men, 639
 importation of, spatial bridging in, 742, 750 (editorial)
 in incarcerated women
 preferred sampling methods of, 306
 surveillance for, 64
 increased incidence of, in Finland, 737

male, epidemiologic trends in, in Spain, 280
 molecular epidemiology of, in Iceland, 249
 partner notification for, low coverage of, 490
 patient-delivered partner therapy with azithromycin for, 49
 patient-delivered therapy for, 509
 in pregnant African American teens with older partners, 211, 214 (editorial)
 prevalence of
 in female Army recruits, 539, 545 (editorial)
 in female emergency department patients, 335
 in Finland, 737
 in Indonesian sex workers, 671
 in Mexican sex workers, 195
 in pregnant women, in Vauatu, 362
 in ROTC cadets, 901
 screening for. *See also* Screening
 in adolescents, 367 (letter)
 age range for, 120
 in asymptomatic men, ligase chain reaction with/without leukocyte esterase test for, 99
 in community based mobile clinic, 654
 in Indonesian sex workers, 671
 at male-only saunas, 320
 risk factor vs. clinically based, 901
 sentinel site surveillance for, 20
 serovar-clinical manifestations correlation in, 160
 syndromic management of, in China, 327
 urine testing for
 in males, 345
 self-sampling methods for, 306, 769

Chlamydia trachomatis
 genotyping of, contact tracing and, 205
 serovars of, longitudinal assessment of, 357
 Cigarette smoking, HSV-2 infection and, 405
 Ciprofloxacin, gonococcal resistance to. *See also* Antimicrobial resistance
 in India, 523
 in Spain, 395
 Circumcision, HSV-2 infection in females and, 405
 Clinic attendees. *See* Family planning clinic attendees; Sexually transmitted disease clinic attendees
 College students. *See also* Adolescents
 acceptability of STD vaccination in, 774
 genital herpes in, HSV type 1 as predominant cause of, 797
 Commercial sex workers. *See* Sex workers
 Community-based screening, effectiveness of, 654, 659 (editorial)
 Community pharmacists, as treatment providers
 in Peru, 379
 in South Africa, 609
 Compliance, with antiretroviral therapy, transmission risk behaviors and, 399
 Concurrency, quantitative assessment of, 6
 Condom use. *See also* Risk behavior/factors
 acceptability and product choice as indicators of, 556
 by adjudicated African American adolescents, 634
 female condoms
 acceptability and product choice as indicators of, 556
 patterns and predictors of, 91, 556
 use-effectiveness of, 433, 440 (editorial)
 by HIV-infected persons, in rural areas, 134
 with hormonal contraceptives
 by adolescents, 719
 by HIV-infected vs. non-HIV-infected women, 809
 by older women, 216
 promotion of, in China, 600
 by sex workers, in Peru, 273
 Condylomata acuminata
 frequently asked questions about, 193
 imiquimod 5% cream for, 124
 Contact tracing. *See* Partner notification
 Contraceptives
 barrier. *See also* Condom use
 acceptability and product choice as indicators of use of, 556
 oral, condom use with
 by adolescents, 719
 by HIV-infected vs. non-HIV-infected women, 809
 Core groups
 geographic stability of, 825 (editorial)
 stability of sexual behavior in, 818
 Correspondence, 183, 185, 367, 368, 526, 528, 531
 Cost, average lifetime, of pelvic inflammatory disease, 369
 Cost effectiveness
 of azithromycin, for incubating syphilis, 502
 of diagnosis and treatment protocols for chlamydia and gonorrhea, in Africa, 455
 of syndromic management in pharmacies
 in Peru, 379
 in South Africa, 609
 Côte d'Ivoire, treatment algorithms for bacterial vaginosis in sex workers in, 284
 Counseling, telephone, in Italy, 707
 Cross-border sexual networks, in Hong Kong, 827
 Cuba, drug-resistant *N. gonorrhoeae* in, 10, 443

D

Day laborers, urban immigrant, STD prevalence among, 661
 Detained African American adolescents, risk behavior of, 634
 Developing countries. *See also* specific countries
 adolescent risk behaviors in, 320
 bacterial vaginosis in
 rapid diagnostic kit for, 483
 treatment algorithms for sex workers in, 284
 cost-effectiveness of diagnosis and treatment protocols for chlamydia and gonorrhea in, 455
 drug-resistant *N. gonorrhoeae* in, 10, 178, 443
 genital ulcer disease in, etiology and HIV co-infection in, 114
 HIV-1 transmission in, migration and, 149
 HIV prevalence in, 183, 185 (letters)
 HIV risk factors in, 187, 262
 HPV distribution in family planning clinic attendees in, 137
 HSV type 2 infection in
 prevalence of, 187, 588
 risk factors for, 187, 262
 laboratory testing for STDs and HIV infection in, 905
 N. gonorrhoeae antimicrobial susceptibility in, 25, 178
 participatory mapping of sex trade in, 664
 rapid diagnostic kit for bacterial vaginosis in, 483
 sexual partnership and concurrency in, quantitative assessment of, 6
 sex workers in
 sociodemographic dynamics and STDs in, 266
 STD treatment algorithms for, 284
 STD prevalence in pregnancy in, 362
 STD prevention in, for sex workers, 273
 syndromic management in, role of community pharmacists in, 609
 syndromic management in pharmacies in, 379, 609
 syndromic management of male STDs in, 327
 uneven HIV prevalence in, 779
 Diagnostic testing, in developing countries, 905
 Discordant sexual partners
 of high-risk adolescents, 234
 of pregnant African American teens, 211, 214 (editorial)
 Douching
 early-onset, health beliefs and high-risk behavior and, 689
 HSV-2 infection and, 405
 reasons for continuing or stopping, 71
 Drug resistance. *See* Antimicrobial resistance
 Drug use. *See* Substance use/abuse
 Dry swab sampling
 for HPV polymerase chain reaction assay, in males, 246
 self-performed, for cervicovaginal specimen collection, 107, 306, 769,

E

Economic factors. *See under Cost*
 Editorials, 10, 46, 90, 214, 232, 440, 659, 750, 801, 825
 Education, patient, for HPV infection, 193
 ELISA, time course to seroconversion by, in HSV-1 infection, 310
 Emergency department patients, female, gonorrhea and chlamydia prevalence in, 335
 Emergency-department screening, in inner city vs. urban sites, 143
 Ethnicity. *See Race/ethnicity*

F

Family planning clinic attendees
 female condom use among, 91
 HPV distribution in, 137
 Female condoms. *See also Condoms*
 acceptability and product choice as indicators of use of, 556
 patterns and predictors of use of, 91, 556
 use-effectiveness of, 433, 440 (editorial)
 FemExam, for bacterial vaginosis, 483
 Financial factors. *See under Cost*
 Finland, chlamydial infection in
 increased incidence of, 737
 screening for, 120
 Fluoroquinolones, resistance to. *See also Antimicrobial resistance*
 CDC treatment guidelines and, 528 (letter)

G

Gambia, rapid diagnostic kit for bacterial vaginosis in, 483
 Gap length, STD transmission and, 221
 Gays. *See Men who have sex with men*
 Genital herpes. *See Herpes simplex virus infection*
 Genital ulcer disease, 124
 HIV coinfection and
 in Tanzania, 114
 treatment response and, 241
 HSV-2 as etiologic agent of, in Tanzania, 114
 syndromic management of, in China, 327
 Genital warts
 frequently asked questions about, 193
 imiquimod 5% cream for, 124
 Geographic stability, of core groups, 825 (editorial)
 Glycosidase activity, in bacterial vaginosis, 257
 Gonorrhea/gonococcal infection
 adolescent risk behaviors and, in Thailand, 320
 chlamydia coinfection in, in young women, 472
 detection of HPV on external genitalia of males with, 629
 drug-resistant
 in Canada, 896
 in Cuba, 11, 443
 in India, 523
 in Indonesia, 25, 178
 in Java, Indonesia, 25
 in Spain, 395
 etiologic and epidemiologic trends in, in Spain, 280
 HPV infection and, in men who have sex with men, 639
 importation of, spatial bridging in, 742, 750 (editorial)
 in incarcerated women, surveillance for, 64
 outbreak of, in northern Alberta, Canada, 497
 partner notification for, low coverage of, 490
 prevalence of
 in female emergency department patients, 335
 in Indonesian sex workers, 671
 in pregnant women, in Vauatu, 362
 in women 15 to 24, 472
 rectal, risk factors for, HIV status and, 813
 screening for. *See also Screening*
 in adolescents, 367 (letter)
 in Indonesian sex workers, 671
 at male-only saunas, 320
 in pregnancy, 728
 syndromic management of
 in China, 327

trichomoniasis treatment in, in Malawi, 516
 treatment algorithms for, for sex workers, in Côte d'Ivoire, 284
 urine testing for, acceptability of to adolescents, 850
 Guatemala, sex workers in, sociodemographic dynamics and STDs in, 266

H

Health-seeking behavior, of male STD clinic attendees with/without regular doctors, 512
 Hepatitis, vaccination for, hepatitis A/B vs. hepatitis B vaccine for, 859
 Hepatitis A, in men who have sex with men
 prevalence of, 425
 risk factors for, 425
 vaccination for, 411, 425, 685, 859
 Hepatitis B
 in men who have sex with men
 prevalence of, 425
 risk factors for, 425
 vaccination in, 411, 425, 449, 685, 859
 risk factors and immunity for, in STD clinic attendees, 914
 Hepatitis C
 in men who have sex with men, 425
 screening for, in STD clinic attendees, 340
 seroprevalence of and risk behaviors for, in STD clinic attendees, 33
 sexual transmission of
 after IUD removal, 470
 rates of, 919
 HerpeSelect ELISA, time course to seroconversion by, in HSV-1 infection, 310
 Herpes simplex virus infection
 genital ulcer disease as, in Tanzania, 114
 HPV infection and, in men who have sex with men, 639
 nodular perianal, in AIDS, 157
 prevalence of and risk factors for, in lesbians, 890
 suppressive vs. episodic treatment for, patients' preference for, 226, 232 (editorial)
 type 1
 in college students, 797
 in first episode, 801 (editorial)
 in Israel, 794
 natural history of, 174
 time course of seroconversion by ELISA in, 311
 type 2
 cervical neoplasia grade and, in Jamaica, 575
 in persons seeking repeat HIV testing, 331
 in pregnant Israeli women, 835
 prevalence of, in Tanzania, 187
 risk factors for
 in females, 405
 in Mexican adolescents and young adults, 549
 in Tanzania, 187
 Highly active antiretroviral therapy
 adherence to, transmission risk behaviors and, 399
 impact of on risk behaviors, 399, 562, 764
 Hispanic day laborers, urban, STD prevalence among, 661
 HIV infection. *See Human immunodeficiency virus infection*
 Homosexuals. *See Lesbians; Men who have sex with men*
 Hong Kong. *See also China*
 behavioral surveillance surveys of male clients of female sex workers in, 620
 cross-border sexual networks in, 827
 Hormonal contraceptives, condom use with
 by adolescents, 719
 by HIV-infected vs. non-HIV-infected women, 809
 Human herpesvirus-8 infection
 in HIV-infected soldiers, 700
 in injection drug users, 199
 Human immunodeficiency virus infection
 adolescent risk behaviors and, in Thailand, 320
 anonymous counseling and testing sites for, treatment of asymptomatic STDs at, 874
 counseling and testing sites for, treatment of asymptomatic STDs at, 874
 dual contraceptive use and, 809

HAART for, impact of on risk behaviors, 399, 562, 765
 human herpes type 8 infection and, in soldiers, 700
 mortality in, as cause of declining syphilis rates, 419
 nodular perianal HSV infection in, 157
 partner notification for
 effects of on sexual behaviors and relationship stability, 75, 83
 low coverage of, 490
 prevalence in, in Malawi, 183, 185 (letters)
 risk behaviors/factors for
 in Brazil, 166
 changing perspectives on, 764
 impact of HAART on, 562, 764
 in Madagascar, 262
 in Malawi, 183, 185 (letters)
 in rural areas, 134
 screening for. *See* Screening
 seropositivity for
 disclosure of by patient, 731
 dual condom use by women and, 809
 risk behaviors for rectal gonorrhea and, 813
 among STD clinic attendees, in Spain, 876
 symptomatic management of bacterial vaginosis in, 1
 testing for, perceptions of risk and, 764
 transmission of, effect of migration on, in South Africa, 149
 treatment response in genital ulcer disease and, 241
 trichomoniasis in, associated factors in, 839
 uneven prevalence of, in Africa, 779
 Human papillomavirus DNA, detection of on external genitalia of males with urethritis, 629
 Human papillomavirus infection
 asymptomatic, in males with urethritis, 629
 cervical, in Spain, 788
 cervical neoplasia grade in, STD coinfections and, in Jamaica, 575
 in family planning clinic attendees, in Kenya, 137
 frequently asked questions about, 193
 with multiple HPV types, age and cytologic abnormalities and, 581
 PCR assay for, sampling methods for, 246
 prevalence of, in Argentine women, 593
 Human T-cell lymphotropic virus type I, cervical neoplasia grade and, in Jamaica, 575

I

Iceland, chlamydial infection in, molecular epidemiology of, 249
 Imiquimod 5% cream, for external genital and perianal warts, 124
 Immigrant day laborers, urban, STD prevalence among, 661
 Immunization
 for hepatitis
 hepatitis A/B vs. hepatitis B vaccine for, 859
 for men who have sex with men, 411, 425, 449, 685
 among STD clinic attendees, 914
 for STDs, acceptability of among college students, 774
 Incarcerated persons
 African American adolescent, risk behavior of, 634
 female
 chlamydia in
 preferred sampling methods for, 306
 surveillance for, 64
 epidemiologic study on STDs in, 531 (letter)
 gonorrhea in, surveillance for, 64
 India, ciprofloxacin- and penicillin-resistant *N. gonorrhoeae* in, 523
 Indonesia
 laboratory testing for STDs and HIV infection in, 905
 N. gonorrhoeae antimicrobial susceptibility in, 25, 178
 sex workers in
 gonorrhea/chlamydia screening in, 671
 STD prevalence in, 671
 Injection drug use
 HIV prevalence and, in Brazil, 166
 human herpesvirus type 8 infection and, 199
 by sex workers, in Russia, 46 (editorial)
 Internet, as information resource, for at-risk populations, 15
 Intervention scenarios, mathematical tools for, 388

Intrauterine device, hepatitis C transmission after removal of, 470
 Intravenous drug use. *See* Injection drug use
 Israel
 genital herpes in, HSV type 1 as predominant cause of, 794
 HSV type 2 in pregnant women in, 835
 Italy, telephone hotline in, 707

J

Jamaica, cervical neoplasia grade in, STD coinfections and, 575
Java, N. gonorrhoeae antimicrobial susceptibility in, 25

K

Kenya, HPV distribution in family planning clinic attendees in, 137
 Klausner, Jeffrey, ASTDA Young Investigator Award recipient, 477

L

Laboratory testing, in developing countries, 905
Lactobacillus crispatus capsules, single-use safety study of, 568
 Latino immigrant day laborers, urban, STD prevalence among, 661
 Latvia, sexual habits and HPV infection in females in, 680
 Lesbians, HSV infection in, prevalence of and risk factors for, 890
 Letters to editor, 183, 185, 367, 368, 526, 528, 531, 531531
 Leukocyte esterase test, for chlamydial infection, in asymptomatic males, 99
 Lice, pubic, epidemiology of, 292
 Ligase chain reaction, with/without leukocyte esterase test, for chlamydial infection, in asymptomatic males, 99

M

Madagascar
 HIV risk factors in, 262
 participatory mapping of sex trade in, 664
 Malawi
 HIV prevalence and risk factors in, 183, 185 (letters)
 syndromic treatment of urethritis in, trichomoniasis treatment in, 516
 Male-to-male sexual activity. *See* Men who have sex with men
 Managed care organizations, adherence to CDC guidelines for chlamydial infections in, 30
 Mapping of sex trade, in Madagascar, 664
 Mathematical tools, for assessing effectiveness of intervention scenarios, 388
 Men who have sex with men
 gonorrhea and chlamydia screening in, 886
 at male-only saunas, 886
 hepatitis vaccination for, 411, 425, 449, 685, 859
 HPV infection in, STD coinfession and, 639
 pubic lice in, 292
 risk behaviors of
 availability of HAART and, 562
 in Canadian syphilis outbreak, 315
 at sex resorts, 909
 self-reported sexual activity of, 526 (letter)
 syphilis outbreak among, 872
 young African American, hepatitis B vaccination in, 449
 Metronidazole, for trichomoniasis, in syndromic treatment of urethritis, in Malawi, 516
 Mexico
 chlamydia prevalence in, 195
 HSV-2 infection in, sexual and demographic risk factors for, in adolescents and young adults, 549
 sex workers in, sociodemographic dynamics and STDs in, 266
 urban day laborers from, STD prevalence among, 661
 Microbicides
 N. gonorrhoeae resistance to
 in Canada, 896
 in Cuba, 11, 443
 in India, 523
 in Indonesia, 25, 178
 in Spain, 395
 prophylactic, for syphilis, 844
 topical, acceptability of to adolescent girls, 854

Microwell-plate-based PCR assay, for *Mycoplasma genitalium*, 756
 Migrant laborers, urban Latino, STD prevalence among, 661

Military recruits

- female, chlamydia prevalence in, 539, 545 (editorial)
- male, HIV-infected, human herpesvirus-8 in infection in, 713

Mobile community-based screening, effectiveness of, 654, 659 (editorial)

Mycoplasma genitalium, microwell-plate-based PCR assay for, 756

N

Neisseria gonorrhoeae, antimicrobial susceptibility of

- in Canada, 896
- in Cuba, 11, 443
- in India, 523
- in Indonesia, 25, 178
- in Spain, 395

Netherlands, HPV infection in gay men in, STD coinfection and, 639

New Independent States of Soviet Union, sexual habits and HPV infection in females in, 680

Nodular perianal herpes simplex virus infection, in AIDS, 157

Nongonococcal urethritis

- chronic, chlamydial hsp60 antibodies in, 129
- detection of HPV DNA on external genitalia of males with, 629

Notification. *See* Partner notification

O

Oral contraceptives, condom use with

- by adolescents, 719
- by HIV-infected vs. non-HIV-infected women, 809

P

Papanicolaou test, for trichomoniasis, 694

Parran Award Lecture, 477, 478

Partner age

- in discordant adolescent sex partnerships, 234
- STD prevalence in adolescent girls and, 211, 214 (editorial), 234

Partner notification

- barriers to, 90 (editorial)
- for chlamydial infection, genotyping and, 205
- for HIV and syphilis, effects of on sexual behaviors and relationship stability, 75, 83
- low coverage for gonorrhea, chlamydial infection, and HIV infection in, 490

Patient-delivered therapy, for chlamydial infection, 509

Patient education, for HPV infection, 193

Patient-performed sample collection, for cervicovaginal specimens, 107, 306, 769, 880

Pelvic inflammatory disease

- average lifetime cost of, 369
- clinical diagnostic codes for CDC case definition, predictive value of, 866

Penicillin. *See also* Antibiotics

- N. gonorrhoeae* resistance to
 - in Canada, 896
 - in Cuba, 10, 443
 - in India, 523
 - in Indonesia, 25, 178
 - in Spain, 395

Perianal nodular herpes simplex virus infection, in AIDS, 157

Perianal warts, imiquimod 5% cream for, 124

Peru

- cost-effectiveness of syndromic management in pharmacies in, 379
- STD prevention in, for sex workers, 273

Pharmacies, syndromic management in

- in Peru, 379
- in South Africa, 609

Phthirus pubis, epidemiology of, 292

Polymerase chain reaction assay

- for HPV, sampling methods for, 246
- microwell-plate-based, for *Mycoplasma genitalium*, 756

Pregnancy

- in African American teens, older partners and STD prevalence among, 211, 214 (editorial)
- bacterial vaginosis in
 - management of, 645

preterm labor and, 645

continued risky sex during, among African American adolescents, 57

gonorrhea screening in, 728

HSV-2 infection in, in Israel, 835

STD prevalence in, in Vanuatu, 362

Preterm labor, bacterial vaginosis and, 645

Prevention

Internet information sources for, 15

needs assessment for, in China, 600

in sex workers, in Peru, 273

state policy support for, 614

Prisoners

African American adolescent, risk behavior of, 634

female

chlamydial infection in

preferred sampling methods for, 306

surveillance for, 64

epidemiologic study on STDs in, 531 (letter)

gonorrhea in, surveillance for, 64

Prostitution. *See* Sex workers

Protease inhibitors, incidence of trichomoniasis in HIV infection and, 839

Proteinase activity, in bacterial vaginosis, 257

Psychosocial factors, in vaccination for hepatitis C, in young African American gay men, 449

Pubic lice, epidemiology of, 292

Public health clinic attendees. *See* Sexually transmitted disease clinic attendees

R

Race/ethnicity. *See also* African Americans

chlamydia and gonorrhea in incarcerated women and, 64

concordance between sexual behavior and sexual identity and, 110

emergency-department screening in inner city vs. urban sites and, 143

STD prevalence among urban day laborers and, 661

Reactor grids, in syphilis surveillance, 650

Rectal gonorrhea, risk factors for, HIV status and, 813

Reporting of, male-to-male sexual activity, 526 (letter)

Risk behaviors/factors. *See also* Condom use; Sexual behavior; Substance use/abuse

of adjudicated African American adolescents, 634

in cross-border sexual networks, in Hong Kong, 827

discordant sexual partners and, 234

early-onset douching and, 689

effects of partner notification on, 75, 83

emotional experience of intercourse as, 348

of females in New Independent States of Soviet Union, 680

heterogeneity of, treatment planning and, 388

for HIV infection

in Brazil, 166

changing attitudes toward, 764

impact of HAART on, 399, 562, 764

in Madagascar, 262

in Malawi, 183, 185 (letters)

in rural areas, 134

in HSV-2 infection, in females, 405

of males with/without regular doctors, 512

of men who have sex with men, at sex resorts, 909

in pregnant African American teens, 57, 211, 214 (editorial)

stability of, in birth cohort, 818

in Thailand, 320

Risk spaces, core group concept and, 825 (editorial)

Rothenberg, Richard, Thomas Parran Award recipient, 477, 478

Russia

sexual habits and HPV infection in females in, 680

sex workers in

injection drug use by, 46 (editorial)

social organization of, 39

S

Sample collection, cervicovaginal, patient-performed, 107, 306, 769, 880

Sauna, male-only, gonorrhea and chlamydia screening in, 886

Screening

for chlamydia
 in adolescents, 367 (letter)
 age range for, 120
 in asymptomatic men, ligase chain reaction with/without leukocyte esterase test for. *See* Race/ethnicity
 in community based mobile clinic, 654, 659 (editorial)
 at male-only saunas, 886
 risk factor vs. clinically based, 901
 emergency-department, in inner city vs. urban sites, 143
 for gonorrhea
 in Indonesian sex workers, 671
 at male-only saunas, 886
 in pregnancy, 728
 for hepatitis C, in STD clinic attendees, 340
 for Medicaid patients, 723
 mobile community-based, effectiveness of, 654, 659 (editorial)
 for Peruvian sex workers, 273
 Self-sampling, for cervicovaginal secretions, 107, 306, 769, 880
 Sentinel site surveillance, for chlamydial infection, 20
 Sex resorts, for gay men, risk behavior at, 909
 Sex trade. *See also* Sex workers
 participatory mapping of, in Madagascar, 664
 Sexual activity, male-to-male. *See also* Men who have sex with men reporting of, 526 (letter)
 Sexual behavior. *See also* Risk behaviors/factors
 concordance of with sexual identity, racial/ethnic variations in, 110
 female adolescent, nonexclusivity in romantic relationships in, 752
 of females in New Independent States of Soviet Union, 680
 of older women, 216
 stability of, in birth cohort, 818
 Sexual concurrency, quantitative assessment of, 6
 Sexual debut, douching and, 689
 Sexually transmitted disease clinic attendees
 female condoms use by, 91
 hepatitis C screening in, 340
 hepatitis C seroprevalence and risk behaviors in, 33
 HIV seroprevalence in, 876
 Internet use by, 33
 public lice in, epidemiology of, 292
 risk factors and immunity for hepatitis B in, 914
 treatment of symptomatic STDs at, 512
 with/without regular doctors, STD burden and risk in, 512
 Sexually transmitted diseases. *See also* specific diseases
 CDC treatment guidelines for, need for revision of, 528 (letter)
 in incarcerated women, epidemiologic study of, 531 (letter)
 prevalence of
 in pregnant women, in Vanuatu, 362
 among urban Latino day laborers, 661
 prevention of
 Internet information sources for, 15
 needs assessment for, in China, 600
 in sex workers, 273
 state policy support for, 614
 risk factors for. *See* Risk behaviors/factors
 screening for. *See* Screening
 syndromic treatment of, in China, 327
 transmission dynamics in (Thomas Parran Award Lecture), 478
 transmission of, gap length and, 221
 Sexual mixing, spatial bridging and, in importation of gonorrhea and chlamydia, 742, 750 (editorial)
 Sexual networks, cross-border, in Hong Kong, 827
 Sexual partnerships
 discordant
 of high-risk adolescents, 234
 of pregnant African American teens, 211, 214 (editorial)
 gap length between, STD transmission and, 221
 quantitative assessment of, 6
 targeting meeting places for, in response to syphilis outbreak, 533
 Sex workers
 chlamydia prevalence in, in Mexico, 195
 drug-resistant *N. gonorrhoeae* in, in Indonesia, 178
 enumeration of, in Madagascar, 664
 injection drug use by, in Russia, 46
 male, drug injection and sexual mixing patterns of, 571
 male clients of, behavioral surveillance surveys of, in Hong Kong, 620
 participatory mapping for, in Madagascar, 664
 screening for gonorrhea and chlamydial infection in, in Indonesia, 671
 social organization of, in Moscow, 39
 sociodemographic dynamics and STDs in, at Mexican-Guatemalan border, 266
 STD prevalence in, in Indonesia, 671
 STD prevention in, 273
 STD treatment algorithms for, in Côte d'Ivoire, 284
 SIS model, for assessment of intervention scenarios, 388
 Smoking, HSV-2 infection and, 405
 Soldiers
 female, chlamydia prevalence in, 539, 545 (editorial)
 male, HIV-infected, human herpesvirus-8 in infection in, 713
 South Africa
 HIV-1 transmission in, migration and, 149
 syndromic management in, role of community pharmacists in, 609
 Soviet Union, New Independent States of, sexual habits and HPV infection in females in, 680
 Spain
 cervical HPV infection in, 788
N. gonorrhoeae resistance to ciprofloxacin in, 395
 seroprevalence among STD clinic attendees in, 876
 urethritis in, etiologic and epidemiologic trends in, 280
 Spatial bridging, in importation of gonorrhea and chlamydia, 742, 750 (editorial)
 Specimen collection
 of cervicovaginal secretions
 method preferred by incarcerated women, 306
 self-sampling methods for, 107, 306, 769, 880
 urine, for chlamydial infection, in males, 345
 Spermicides, acceptability and product choice as indicators of use of, 556
 Students. *See* Adolescents; College students
 Substance use/abuse. *See also* Risk behaviors/factors
 by adjudicated African American adolescents, 634
 HIV prevalence and, in Brazil, 166
 HIV risk and, changing perspectives on, 764
 human herpesvirus type 8 infection and, 199
 by male sex workers, drug injection and sexual mixing patterns of, 571
 by sex workers, in Russia, 46 (editorial)
 Swabs
 dry, for HPV polymerase chain reaction assay, in males, 246
 self-collected, for cervicovaginal specimen collection, 107, 306, 769, 880
 Syndromic management
 of bacterial vaginosis, with/without HIV-1 coinfection, 1
 of male STDs, in China, 327
 role of community pharmacists in
 in Peru, 379
 in South Africa, 609
 Syphilis
 antibiotic prophylaxis for, 844
 declining rates of, AIDS mortality as cause of, 419
 incubating, azithromycin for, cost-effectiveness of, 502
 mass treatment of, 297
 outbreak of
 among men who have sex with men, 872
 targeting sex partner meeting location for, 533
 partner notification for, effects of on sexual behaviors and relationship stability, 75, 83
 patient characteristics with male-to-male vs. heterosexual acquisition in, in Canada, 310
 prevalence of, in pregnant women, in Vanuatu, 362
 screening for. *See also* Screening
 in Medicaid patients, 723
 surveillance for, reactor grids in, 650
 syndromic management of, in China, 327
 Syphilis reactor grids, 700

T

Tanzania
genital ulcer disease in, etiology and HIV coinfection in, 114
HSV-2 infection in
prevalence of, 187, 588
risk factors for, 187

Telephone hotline, in Italy, 707

Tetracycline, *N. gonorrhoeae* resistance to, 10
in Canada, 896
in Cuba, 10, 443
in India, 523
in Indonesia, 25, 178
in Spain, 395

Thailand, adolescent risk behaviors in, 320

Third world countries. *See* Developing countries

Thomas Parran Award Lecture, 477, 478

Topical microbicide, acceptability of to adolescent girls, 854

Transmission dynamics (Thomas Parran Award Lecture), 478

Treatment, syndromic. *See* Syndromic management

Treatment adherence, HIV-transmission risk behaviors and, 399

Treatment planning, mathematical tools for, 388

Trichomoniasis
in HIV infection, associated factors in, 839
Papanicolaou test for, 694
prevalence of, in pregnant women, in Vanuatu, 362
treatment of
for sex workers, in Côte d'Ivoire, 284
in syndromic management of urethritis, in Malawi, 516

U

Ulcers. *See* Genital ulcer disease

Uncircumcised males, HSV-2 infection in females and, 405

Ureaplasma urealyticum urethritis, epidemiologic trends in, in Spain, 280

Urethral discharge, syndromic management of, in China, 327

Urethritis
detection of HPV DNA on external genitalia of males with, 629
gonococcal. *See* Gonorrhea/gonococcal infection
nongonococcal
chronic, chlamydial hsp60 antibody in, 129
etiological and epidemiologic trends in, in Spain, 280
syndromic management of, trichomoniasis treatment in, in Malawi, 516

Urine testing

for chlamydial infection
acceptability of to adolescents, 850
in males, 345

for gonorrhea, acceptability of to adolescents, 850
vs. self-collected vaginal swab
female military recruits' preference for, 769
incarcerated women's preference for, 306

V

Vaccination
for hepatitis
hepatitis A/B vs. hepatitis B vaccine for, 859
for men who have sex with men, 411, 425, 449, 685
among STD clinic attendees, 914

for STDs, acceptability of among college students, 774

Vaginal discharge
rapid diagnostic kit for, in Gambia, 483
syndromic management of, with/without HIV-1 coinfection, 1

Vaginal douching
early-onset, health beliefs and high-risk behavior and, 689

HSV-2 infection and, 405
reasons for continuing or stopping, 71

Vaginal flora
abnormal. *See* Bacterial vaginosis
effect of single-use *Lactobacillus crispatus* capsules on, 568

Vaginal swabs, self-collected, for cervicovaginal specimen collection, 107, 306, 769, 880

Vaginitis, treatment algorithms for, for sex workers, in Côte d'Ivoire, 284

Vaginosis. *See* Bacterial vaginosis

Valacyclovir, for genital herpes, in suppressive vs. episodic therapy, patients' preference for, 226, 232 (editorial)

Vanuatu, STD prevalence in pregnancy in, 362

W

Warts, anogenital
5% imiquimod cream for, 124
frequently asked questions about, 193

Y

Young Investigator Award (ASTDA), 477

